Trial Profile
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients With Advanced Solid Malignancies and Expansion in Select Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2023
Price :
$35
*
At a glance
- Drugs Abequolixron (Primary) ; Nivolumab (Primary) ; Carboplatin; Docetaxel; Ipilimumab; Pembrolizumab; Pemetrexed
- Indications Bladder cancer; Carcinoma; Fallopian tube cancer; Liver cancer; Lymphoma; Malignant melanoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Inspirna
- 21 Jul 2022 Planned number of patients changed from 135 to 150.
- 21 Jul 2022 Planned End Date changed from 1 Mar 2022 to 1 May 2024.
- 21 Jul 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.